Zymeworks (ZYME)
(Delayed Data from NSDQ)
$10.40 USD
+0.02 (0.19%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $10.40 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth B Momentum F VGM
Zymeworks Inc. (ZYME) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$13.94 | $20.00 | $10.00 | 34.30% |
Price Target
Based on short-term price targets offered by eight analysts, the average price target for Zymeworks Inc. comes to $13.94. The forecasts range from a low of $10.00 to a high of $20.00. The average price target represents an increase of 34.3% from the last closing price of $10.38.
Analyst Price Targets (8 )
Broker Rating
Zymeworks Inc. currently has an average brokerage recommendation (ABR) of 1.75 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by eight brokerage firms. The current ABR compares to an ABR of 1.75 a month ago based on eight recommendations.
Of the eight recommendations deriving the current ABR, five are Strong Buy, representing 62.5% of all recommendations. A month ago, Strong Buy represented 62.5%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 5 | 5 | 5 | 5 | 5 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 3 | 3 | 3 | 3 | 3 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.75 | 1.75 | 1.75 | 1.75 | 1.75 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
5/2/2024 | SVB Securities | Andrew Berens | Hold | Hold |
4/15/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
3/15/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
3/12/2024 | Wells Fargo Securities | Derek C Archila | Strong Buy | Strong Buy |
3/11/2024 | H.C. Wainwright & Co. | Robert Burns | Hold | Hold |
3/7/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
12/11/2023 | Bloom Burton & Company | David Martin | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.75 |
ABR (Last week) | 1.75 |
# of Recs in ABR | 8 |
Average Target Price | $13.94 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 85 of 252 |
Current Quarter EPS Est: | -0.10 |